Revolution Medicines reported $198 million in revenue for Q3, driven by the U.S. launch of its cancer drug RASONQUE, which has treated over 5,000 patients since FDA approval. The drug shows clear benefits over chemotherapy for pancreatic cancer and is being tested for other cancers, supporting the company's multi-asset pipeline. Despite strong early sales, the company's $40 billion valuation has led to cautious investor sentiment, with expectations for sustained commercial success or major clinical trial results before further stock gains. The analyst maintains a Hold rating, awaiting full-year revenue confirmation or significant Phase 3 trial outcomes.
Revolution Medicines shares are trading at USD 182.80 on Pluang as of Nov 06, 2026 03:02 WIB, down 8.46% in one day. The stock's market cap stands at $42.80 billion, slightly above the article's mentioned valuation. Trading volume reached 2,494,920 shares, reflecting active investor interest despite cautious sentiment.
